Literature DB >> 16697115

Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.

C Winkler1, B Georgievska, T Carlsson, B Lacar, D Kirik.   

Abstract

Functional recovery following intrastriatal transplantation of fetal dopaminergic neurons in animal models of Parkinson's disease is, at least in part, dependent on the number of surviving dopaminergic neurons and the degree of graft-derived dopaminergic reinnervation of the host striatum. In the present study, we analyzed whether continuous exposure of glial cell line-derived neurotrophic factor (GDNF) to mature dopaminergic grafts could further boost the functional outcome of widespread intrastriatal dopaminergic grafts. Rats with dopamine-denervating lesions received multiple intrastriatal transplants of fetal dopaminergic cells and graft-induced behavioral effects were analyzed in drug-induced and spontaneous motor behaviors. At three months after grafting, animals received intrastriatal injections of recombinant lentiviral vectors encoding for either human GDNF or the green fluorescent protein. Continuous exposure of GDNF to the grafts did not boost the functional recovery beyond what was observed in the control animals. Rather, in some of the spontaneous motor behaviors, animals in the GDNF-group showed deterioration as compared with control animals, and this negative effect of GDNF was associated with a down-regulation of the tyrosine hydroxylase enzyme. Based on these and our earlier results, we propose that intrastriatal administration of GDNF at the time of or shortly after grafting is highly effective in initially promoting the cell survival and fiber outgrowth from the grafts. However, once the grafts are mature, GDNF's ability to boost dopaminergic neurotransmission follows the same dynamics as for the native nigral dopaminergic neurons, which appears to be dependent on the concentration of GDNF. Since rather low doses of glial cell line-derived neurotrophic factor at nanogram levels appear to saturate these effects, it may be critical to adjust GDNF levels using tightly regulated gene expression systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697115     DOI: 10.1016/j.neuroscience.2006.03.068

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

Review 1.  How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Authors:  Jia Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

2.  Effects of glial cell line-derived neurotrophic factor deletion on ventral mesencephalic organotypic tissue cultures.

Authors:  Sara af Bjerkén; Heather A Boger; Matthew Nelson; Barry J Hoffer; Ann-Charlotte Granholm; Ingrid Strömberg
Journal:  Brain Res       Date:  2006-12-19       Impact factor: 3.252

3.  Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion.

Authors:  Marco Timmer; Konstantin Cesnulevicius; Christian Winkler; Julia Kolb; Esther Lipokatic-Takacs; Julia Jungnickel; Claudia Grothe
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

4.  Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.

Authors:  Timothy J Collier; Jennifer O'Malley; David J Rademacher; Jennifer A Stancati; Kellie A Sisson; Caryl E Sortwell; Katrina L Paumier; Kibrom G Gebremedhin; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2015-03-11       Impact factor: 5.996

Review 5.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

7.  Regulated expression of lentivirus-mediated GDNF in human bone marrow-derived mesenchymal stem cells and its neuroprotection on dopaminergic cells in vitro.

Authors:  Wei-Hua Yang; Chun Yang; Yue-Qiang Xue; Tao Lu; Jakob Reiser; Li-Ru Zhao; Wei-Ming Duan
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

8.  Simultaneous Transplantation of Fetal Ventral Mesencephalic Tissue and Encapsulated Genetically Modified Cells Releasing GDNF in a Hemi-Parkinsonian Rat Model of Parkinson's Disease.

Authors:  Alberto Perez-Bouza; Stefano Di Santo; Stefanie Seiler; Morten Meyer; Lukas Andereggen; Alexander Huber; Raphael Guzman; Hans R Widmer
Journal:  Cell Transplant       Date:  2017-09       Impact factor: 4.064

Review 9.  Combination of cell transplantation and glial cell line-derived neurotrophic factor-secreting encapsulated cells in Parkinson's disease.

Authors:  Hans R Widmer
Journal:  Brain Circ       Date:  2018-10-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.